% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{vanVliet:137647,
author = {van Vliet, Erwin and Daneshian, Mardas and Beilmann, Mario
and Davies, Anthony and Fava, Eugenio and Fleck, Roland and
Julé, Yvon and Kansy, Manfred and Kustermann, Stefan and
Macko, Peter and Mundy, William R and Roth, Adrian and Shah,
Imran and Uteng, Marianne and van de Water, Bob and Hartung,
Thomas and Leist, Marcel},
title = {{C}urrent approaches and future role of high content
imaging in safety sciences and drug discovery.},
journal = {Alternatives to animal experimentation},
volume = {31},
number = {4},
issn = {1868-596X},
address = {Heidelberg},
publisher = {Springer},
reportid = {DZNE-2020-03969},
pages = {479-493},
year = {2014},
abstract = {High content imaging combines automated microscopy with
image analysis approaches to simultaneously quantify
multiple phenotypic and/or functional parameters in
biological systems. The technology has become an important
tool in the fields of safety sciences and drug discovery,
because it can be used for mode-of-action identification,
determination of hazard potency and the discovery of
toxicity targets and biomarkers. In contrast to conventional
biochemical endpoints, high content imaging provides insight
into the spatial distribution and dynamics of responses in
biological systems. This allows the identification of
signaling pathways underlying cell defense, adaptation,
toxicity and death. Therefore, high content imaging is
considered a promising technology to address the challenges
for the 'Toxicity testing in the 21st century' approach.
Currently, high content imaging technologies are frequently
applied in academia for mechanistic toxicity studies and in
pharmaceutical industry for the ranking and selection of
lead drug compounds or to identify/confirm mechanisms
underlying effects observed in vivo. A recent workshop
gathered scientists working on high content imaging in
academia, pharmaceutical industry and regulatory bodies with
the objective to compile the state-of-the-art of the
technology in the different institutions. Together they
defined technical and methodological gaps, proposed quality
control measures and performance standards, highlighted cell
sources and new readouts and discussed future requirements
for regulatory implementation. This review summarizes the
discussion, proposed solutions and recommendations of the
specialists contributing to the workshop.},
keywords = {Animal Testing Alternatives / Animals / Drug Discovery:
methods / Hazardous Substances / Imaging, Three-Dimensional:
methods / Models, Biological / Pharmaceutical Preparations /
Predictive Value of Tests / Reproducibility of Results /
Toxicity Tests: methods / Hazardous Substances (NLM
Chemicals) / Pharmaceutical Preparations (NLM Chemicals)},
cin = {AG Fava 1},
ddc = {610},
cid = {I:(DE-2719)1013016},
pnm = {342 - Disease Mechanisms and Model Systems (POF3-342)},
pid = {G:(DE-HGF)POF3-342},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:25027442},
doi = {10.14573/altex.1405271},
url = {https://pub.dzne.de/record/137647},
}